Double radiation attack aims to stop prostate cancer bone breaks
NCT ID NCT07354594
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding precise external beam radiation to standard radioligand therapy can better control metastatic prostate cancer that no longer responds to hormone therapy. About 120 participants will receive either standard treatment alone or combined with targeted radiation to under-treated tumors. The main goal is to reduce bone complications like fractures or spinal cord compression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium-177 PSMA radioligand therapy plus external beam radiotherapy
What this could lead to
If successful, this could offer a more personalized, effective way to control metastatic prostate cancer and reduce painful bone events.
What could go wrong
This is a small, early-phase trial (120 people) testing a new combination. It may not improve outcomes or could increase side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Hospitalier de l'Université-de-Montréal
Montreal, Quebec, H2X 3E4, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••